Is the trial design suitable for the U.S. market?
Review indication fit, endpoint logic, eligibility burden, biomarker requirements, and whether the U.S. evidence story is credible before execution begins.
Why before CRO
Because the CRO will execute the plan. Whether the plan itself holds up is a sponsor-side judgment. OncoLattice does not replace the CRO; we help sponsors ask the hard questions before budget is committed.
CROs are essential execution partners.
They are built to run trials: site startup, project management, monitoring, data management, and clinical operations. But before execution, China-based oncology sponsors need a strategy layer that tests whether the plan itself is ready for U.S. FIH or Phase 1 execution.
Review indication fit, endpoint logic, eligibility burden, biomarker requirements, and whether the U.S. evidence story is credible before execution begins.
Pressure-test cohort size, competing studies, diagnostic pathways, and the practical availability of the target population.
Identify design elements that may create avoidable activation delay, screen-failure burden, or site reluctance.
Compare patient distribution, mechanism experience, biomarker capability, PI load, and regional concentration risk.
Enter CRO discussions with a challenge memo, site-list questions, and clear criteria for accepting or revising the plan.
Why before CRO
The distinction is not whether a sponsor needs a CRO. The distinction is when the sponsor should enter CRO execution and with what level of preparation.
The goal is not to delay execution. The goal is to prevent premature execution of a trial design, cohort assumption, or site strategy that has not been tested carefully enough.